



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/535, 31/55, C07D 489/04	A1	(11) International Publication Number: WO 99/51240 (43) International Publication Date: 14 October 1999 (14.10.99)
(21) International Application Number: PCT/US99/07325 (22) International Filing Date: 2 April 1999 (02.04.99) (30) Priority Data: 09/054,916 3 April 1998 (03.04.98) US (71) Applicant (for all designated States except US): THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 12th floor, 1111 Franklin Street, Oakland, CA 94607-5200 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): ROGERS, Gary, A. [US/US]; 3056 Foothill Road, Santa Barbara, CA 93105 (US). JOHNSTRÖM, Peter [SE/SE]; Skondalsvagen 100, S-128 68 Skondal (SE). (74) Agent: COLEMAN, Henry, D.; Coleman Sudol, LLP, 14th floor, 708 Third Avenue, New York, NY 10017-4101 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KB, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: ACYLBENZOXAZINES FOR ENHANCING SYNAPTIC RESPONSE(S) (57) Abstract Compounds based on the benzoxazine ring system that are remarkably more potent than corresponding benzoyl piperidines for enhancing synaptic responses mediated by AMPA receptors are disclosed, as are methods for the preparation thereof, and methods for their use for treatment of subjects suffering from impaired nervous or intellectual functioning due to deficiencies in the number of excitatory synapses or in the number of AMPA receptors. The invention compounds can also be used for the treatment of non-impaired subjects for enhancing performance in sensory-motor and cognitive tasks which depend on brain networks utilizing AMPA receptors and for improving memory encoding.		